Koen Van Besien to Pyrroles
This is a "connection" page, showing publications Koen Van Besien has written about Pyrroles.
Connection Strength
0.149
-
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
Score: 0.149